A Phase I/II, Open-Label Single Institution Study Evaluating Rapamycin in Combination With High-Dose Etoposide and Cytarabine in Relapsed or Refractory Aggressive Lymphoid Malignancies.

Trial Profile

A Phase I/II, Open-Label Single Institution Study Evaluating Rapamycin in Combination With High-Dose Etoposide and Cytarabine in Relapsed or Refractory Aggressive Lymphoid Malignancies.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Cytarabine (Primary) ; Etoposide (Primary) ; Sirolimus (Primary)
  • Indications Acute lymphoblastic leukaemia; Burkitt's lymphoma; Chronic myeloid leukaemia; T cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Sep 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top